Citations

Clear

278 citation(s) found for "Sy, Ethan".

Recurrence after cure in cranial dural arteriovenous fistulas: a collaborative effort by the Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR)
Abecassis, Isaac Josh, Meyer, R. Michael, Levitt, Michael R., Sheehan, Jason P., Chen, Ching-Jen, Gross, Bradley A., Smith, Jessica, Fox, W. Christopher, Giordan, Enrico, Lanzino, Giuseppe, Starke, Robert M., Sur, Samir, Potgieser, Adriaan R. E., Dijk, J. Marc C. van, Durnford, Andrew, Bulters, Diederik, Satomi, Junichiro, Tada, Yoshiteru, Kwasnicki, Amanda, Amin-Hanjani, Sepideh, Alaraj, Ali, Samaniego, Edgar A., Hayakawa, Minako, Derdeyn, Colin P., Winkler, Ethan, Abla, Adib, Lai, Pui Man Rosalind, Du, Rose, Guniganti, Ridhima, Kansagra, Akash P., Zipfel, Gregory J., Kim, Louis J., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Korai, Masaaki, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Aziz-Sultan, M. Ali, Patel, Nirav, Frerichs, Kai U., Derdeyn, Colin P. , Amin‐Hanjani, Sepideh , Bulters, Diederik , Aziz‐Sultan, Mohammad Ali , Giordan, Enrico , Levitt, Michael R. , Hayakawa, M. , Alaraj, Ali , Dijk, J. Marc C. van , Abla, Adib A. , Korai, Masaaki , Levitt, Michael R , Amin-Hanjani, Sepideh , Alaraj, Ali , van DijK, J Marc C , Abla, Adib , Bulters, Diederik O , Derdeyn, Colin P , Abecassis, Isaac Josh, Meyer, R. Michael, Sheehan, Jason P., Chen, Ching-Jen, Gross, Bradley A., Smith, Jessica, Fox, W. Christopher, Giordan, Enrico, Lanzino, Giuseppe, Starke, Robert M., Sur, Samir, Potgieser, Adriaan R. E., Dijk, J. Marc C. van, Durnford, Andrew, Satomi, Junichiro, Tada, Yoshiteru, Kwasnicki, Amanda, Samaniego, Edgar A., Hayakawa, Minako, Derdeyn, Colin P., Winkler, Ethan, Lai, Pui Man Rosalind, Du, Rose, Guniganti, Ridhima, Kansagra, Akash P., Zipfel, Gregory J., Kim, Louis J., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Patel, Nirav, Frerichs, Kai U.

Mayo Clinic

Journal of Neurosurgery | September 10, 2021 | Volume: 136 | Issue: 4 | Pages: 981-989

10.3171/2021.1.jns202033 | PMID 34507283 Get It

OBJECTIVE Cranial dural arteriovenous fistulas (dAVFs) are often treated with endovascular therapy, but occasionally a multimodality approach including surgery and/or radiosurgery is utilized. Recurrence after an initial angiographic cure has been reported, with estimated rates ranging from 2% to 14.3%, but few risk factors have been identified. The objective of this study was to identify risk factors associated with recurrence of dAVF after putative cure. METHODS The Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR) data were retrospectively reviewed. All patients with angiographic cure after treatment and subsequent angiographic follow-up were included. The primary outcome was recurrence, with risk factor analysis. Secondary outcomes included clinical outcomes, morbidity, and mortality associated with recurrence. Risk factor analysis was performed comparing the group of patients who experienced recurrence with those with durable cure (regardless of multiple recurrences). Time-to-event analysis was performed using all collective recurrence events (multiple per patients in some cases). RESULTS Of the 1077 patients included in the primary CONDOR data set, 457 met inclusion criteria. A total of 32 patients (7%) experienced 34 events of recurrence at a mean of 368.7 days (median 192 days). The recurrence rate was 4.5% overall. Kaplan-Meier analysis predicted long-term recurrence rates approaching 11% at 3 years. Grade III dAVFs treated with endovascular therapy were statistically significantly more likely to experience recurrence than those treated surgically (13.3% vs 0%, p = 0.0001). Tentorial location, cortical venous drainage, and deep cerebral venous drainage were all risk factors for recurrence. Endovascular intervention and radiosurgery were associated with recurrence. Six recurrences were symptomatic, including 2 with hemorrhage, 3 with nonhemorrhagic neurological deficit, and 1 with progressive flow-related symptoms (decreased vision). CONCLUSIONS Recurrence of dAVFs after putative cure can occur after endovascular treatment. Risk factors include tentorial location, cortical venous drainage, and deep cerebral drainage. Multimodality therapy can be used to achieve cure after recurrence. A delayed long-term angiographic evaluation (at least 1 year from cure) may be warranted, especially in cases with risk factors for recurrence.
Overall survival and secondary malignant neoplasms in children receiving passively scattered proton or photon craniospinal irradiation for medulloblastoma
Paulino, Arnold C. , Ludmir, Ethan B. , Grosshans, David R. , Su, Jack , McGovern, Susan L. , Okcu, M. Fatih , McAleer, Mary Frances , Baxter, Patricia , Mahajan, Anita , Chintagumpala, Murali , Paulino, Arnold C , Ludmir, Ethan B

Mayo Clinic

Cancer | July 13, 2021 | Volume: 127 | Issue: 20 | Pages: 3865-3871

10.1002/cncr.33783 | PMID 34254296 Get It

BACKGROUNDBoth intensity‐modulated radiotherapy (RT) and passively scattered proton therapy have a risk of secondary malignant neoplasm (SMN) in children. To determine the influence of RT modality on the incidence of SMN after craniospinal irradiation (CSI), the authors compared the incidence of SMN in children who had medulloblastoma treated with either photon CSI plus an intensity‐modulated RT boost (group I) or passively scattered proton CSI plus a boost (group II).METHODSFrom 1996 to 2014, 115 children with medulloblastoma (group I, n = 63; group II, n = 52) received CSI followed by a boost to the tumor bed. Most patients had standard‐risk disease (63.5%). The median follow‐up was 12.8 years for group I and 8.7 years for group II.RESULTSThe 5‐year and 10‐year overall survival (OS) rates were 88.8% and 85.1%, respectively, for standard‐risk patients and 63.1% and 57.3%, respectively, for high‐risk patients, with no OS difference by RT modality (P = .81). Six SMNs were identified (4 in group I, 2 in group II). The 5‐year and 10‐year SMN incidence rates were 1.0% and 6.9%, respectively (0.0% and 8.0%, respectively, in group I; 2.2% and 4.9%, respectively, in group II; P = .74). Two SMNs occurred in the clinical target volume in the brain, 2 occurred in the exit dose region from the photon spinal field, 1 occurred in the entrance path of a proton beam, and 1 occurred outside the radiation field. There were no reported cases of secondary leukemia.CONCLUSIONSThis analysis demonstrates no difference in OS or SMN incidence between patients in groups I and II 10 years after RT.LAY SUMMARY One hundred fifteen children with medulloblastoma received radiotherapy (RT) with either photon craniospinal irradiation (CSI) and an intensity‐modulated RT boost (group I; n = 63) or passively scattered proton CSI and a boost (group II;, n = 52). The majority of children had standard‐risk disease (63.5%). The 5‐year and 10‐year overall survival rates were 88.8% and 85.1% for standard‐risk patients, respectively, and 63.1% and 57.3% for high‐risk patients, respectively, with no difference in overall survival by RT group (P = .81). The 5‐year and 10‐year second malignant neoplasm incidence rates were 1.0% and 6.9%, respectively, with no difference in second malignant neoplasm incidence according to RT group (P = .74).
Abstract 18019: Successful Surgical Management of Severely Symptomatic Hypertrophic Cardiomyopathy Patients With Minimal Septal Hypertrophy
Ahmad, Raabia N, Maron, Barry J. , Rowin, Ethan J. , Haas, Tammy S., Maron, Martin S. , Dearani, Joseph A.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 130 | Issue: suppl_2 | Pages: No page available

10.1161/circ.130.suppl_2.18019 Get It

Background: Marked septal hypertrophy is considered a requirement for effective myectomy in obstructive hypertrophic cardiomyopathy (HCM), with mitral valve replacement recommended as the alternative strategy in patients with minimal hypertrophy. However, it remains uncertain whether relief of obstruction can be effectively abolished without mitral valve replacement in patients with minimal septal wall thickening. Methods: Of 500 patients who underwent surgical myectomy from 2004 to January 2014, 21 (4.2%) were identified with a maximum LV wall thickness ≤ 15mm and constitute the study cohort. Results: All 21 patients (56 ± 10 years old; 62% male) were followed for advanced heart failure symptoms refractory to drug therapy with a maximal septal wall thickness of 13.6 ± 1.7 mm (range: 10-15 mm; ≤ 12 mm in 5 patients). Outflow obstruction ≥ 30 mmHg due to mitral valve-septal contact was present after exercise in 17 of 21 patients (range: 50-150 mmHg), and under resting conditions in 4 patients (range: 30-65 mmHg). In all patients, surgical relief of obstruction consisted of muscular resection of the basal septum with revision of abnormal and apically displaced papillary muscles, which were judged intraoperatively to be contributing to obstruction. In addition, in 10 patients (47%) myectomy alone was not sufficient to relieve obstruction due to the limited opportunity for septal reduction and adjunctive mitral valve repair was performed to shorten an elongated anterior leaflet. No patient required mitral valve replacement or incurred a ventricular septal defect. Post-operatively, 4 patients developed complete heart block requiring permanent pacemaker (1 patient with pre-operative right bundle branch block) and 1 had a cerebrovascular event. At most recent follow up 18 ± 19 months post-myectomy, septal thickness was reduced to 10 ± 2 mm, no patient had an outflow gradient at rest or with provocation, and all patients were alive with the majority asymptomatic (class I: n=13; 62% and class II n=8; 38%). Conclusion: In patients with minimal septal hypertrophy, outflow obstruction can be effectively abolished with surgical myectomy and adjunctive mitral valve repair with a small increased risk of heart block, but without the need for mitral valve replacement.
Abstract 2274: Somatic variant burdenin benign breast disease and association with risk of subsequent breast cancer
Cunningham, Julie M. , Liu, Yuanhang , Bhagwate, Aditya , Heinzen, Ethan P. , McDonough, Samantha J., Winham, Stacey J. , Stallings‐Mann, Melody , Vierkant, Robert A. , Carter, Jodi M. , Sherman, Mark E. , Radisky, Derek C. , Degnim, Amy C. , Wang, Chen

Mayo Clinic

Cancer Research | July 1, 2021 | Volume: 81 | Issue: 13_Supplement | Pages: 2274-2274

10.1158/1538-7445.am2021-2274 Get It

Abstract Benign breast disease (BBD) is an established risk factor for development of breast cancer (BC). However, little is known about the prevalence of somatic genetic alterations at the time of BBD diagnosis and relationship to subsequent BC. To characterize DNA variants in BBD and investigate association with BC risk, we isolated DNA from formalin-fixed paraffin-embedded (FFPE) BBD biopsies and assessed mutations using a panel of 93 breast cancer predisposition genes (Qiagen GeneRead). The study set consisted of 120 BBD patients from three age-matched groups defined based on 16 years of BC follow-up: BBD-controls (cancer-free after 16 years), BBD-ER+, or BBD-ER- breast cancer (within 16 years). Bioinformatics quality checks included comparisons of paired fresh-frozen and FFPE replicates to reduce false variant calls induced by FFPE artifacts. Gene-level variant burden differences among study groups were assessed using 12 statistical approaches, adjusted for patient age, year of biopsy, and histology. To investigate possible immune implications of increased variant burden, extent of leukocytes in the BBD biopsies was assessed using CD45 immunohistochemistry. To assess variant profile changes during the progression from BBD to BC, we also performed targeted sequencing of 12 BBD-matched subsequent tumor samples (six ER+ and six ER-) developed within 5 years of BBD diagnosis. Gene-level association results showed consistently skewed distributions suggesting a higher variant burden in BBD controls: among the top 10 genes associated with case-status (p<0.05), all had BC-risk odds ratio estimates less than 1.0. Immune infiltrates, assessed by CD45 H-scores, were positively associated with overall variant burden (r=0.42, p=0.0031), and noticeably higher in cancer-free controls (r=0.50, p=0.005). Comparison of mutation variants in 12 BBD cases that developed cancer within 5 years of diagnosis and their subsequent tumors revealed that more than half of the non-SNP variants were shared between the BBD and the subsequent tumor (54.6%), whereas less than one quarter were unique to the tumor (20.6%) or unique to the BBD (24.9%). Through BBD-BC paired variant analysis, three subjects were found with newly emergent clones uniquely appearing in the tumors and four subjects had loss of clones in the tumor that were present in the BBD. These results show that somatic variant burden is lower in patients with BBD that progress to BC, mutation profiles of BC progression are heterogeneous, and BBD tissues with reduced variant burden also show reduced immune infiltrate. This implicates a potential protective role for immune activation in BBD. Future directions will define the characteristics of the potentially protective immune response and its role in variant heterogeneity in a larger sample set, integrated with paired RNA sequencing to better understand the pathways involved and the relationship to immune infiltration. Citation Format: Stacey J. Winham, Julie M. Cunningham, Yuanhang Liu, Aditya V. Bhagwate, Ethan P. Heinzen, Samantha J. McDonough, Melody L. Stallings-Mann, Robert A. Vierkant, Jodi M. Carter, Mark E. Sherman, Derek C. Radisky, Amy C. Degnim, Chen Wang. Somatic variant burdenin benign breast disease and association with risk of subsequent breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2274.
Evaluation of Self-Collected Midturbinate Nasal Swabs and Saliva for Detection of SARS-CoV-2 RNA
Boerger, Aimee C. , Buckwalter, Seanne P., Fernholz, Emily C. , Jannetto, Paul J. , Binnicker, Matthew J. , Reed, Katelyn A. , Walchak, Robert C., Woodliff, Ethan D., Johnson, Michael , Pritt, Bobbi S. , Buckwalter, Seanne, Reed, Katelyn, Walchak, Robert, Woodliff, Ethan, Pritt, Bobbi S

Mayo Clinic

Journal of Clinical Microbiology | June 16, 2021 | Volume: 59 | Issue: 9 | Pages: No page available

10.1128/jcm.00848-21 | PMID 34132579 Get It

Rapid and accurate diagnostic testing is essential to bring the ongoing COVID-19 pandemic to an end. As the demand for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing continues to increase amid supply shortages, many laboratories have investigated the use of sources other than nasopharyngeal (NP) swabs.
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening
Requena, David , Ramos‐Espiritu, Lavoisier , Ng, Denise , Bhola, Patrick , Jong, Ype P. de , Wang, Ruisi , Narayan, Nicole J.C., Shebl, Bassem , Michailidis, Eleftherios , Vercauteren, Koen , Hurley, Arlene , Farber, Benjamin A. , Hammond, William J. , Saltsman, James A. , Weinberg, Ethan M. , Glickman, J. Fraser , Lyons, Barbara A. , Ellison, Jessica, Schadde, Erik , Hertl, Martin, Leiting, Jennifer L. , Truty, Mark J. , Smoot, Rory L. , Tierney, Faith, Kato, Tomoaki , Wendel, Hans‐Guido , Rice, Charles M. , Letai, Anthony , Simon, Sanford M. , Requena, David , de Jong, Ype P , Michailidis, Eleftherios , Vercauteren, Koen O A , Hurley, Arlene M , Farber, Benjamin A , Hammond, William J , Glickman, J Fraser , Leiting, Jennifer L , Smoot, Rory L , LaQuaglia, Michael P , Simon, Sanford M , Weinberg, Ethan M , Lalazar, Gadi , Levin, Solomon , Kabbani, Mohammad , LaQuaglia, Michael P. , Coffino, Philip , Torbenson, Michael , Ortiz, Michael V.

Mayo Clinic

Cancer Discovery | June 14, 2021 | Volume: 11 | Issue: 10 | Pages: 2544-2563

10.1158/2159-8290.cd-20-0872 | PMID 34127480 Get It

Abstract To repurpose therapeutics for fibrolamellar carcinoma (FLC), we developed and validated patient-derived xenografts (PDX) from surgical resections. Most agents used clinically and inhibitors of oncogenes overexpressed in FLC showed little efficacy on PDX. A high-throughput functional drug screen found primary and metastatic FLC were vulnerable to clinically available inhibitors of TOPO1 and HDAC and to napabucasin. Napabucasin's efficacy was mediated through reactive oxygen species and inhibition of translation initiation, and specific inhibition of eIF4A was effective. The sensitivity of each PDX line inversely correlated with expression of the antiapoptotic protein Bcl-xL, and inhibition of Bcl-xL synergized with other drugs. Screening directly on cells dissociated from patient resections validated these results. This demonstrates that a direct functional screen on patient tumors provides therapeutically informative data within a clinically useful time frame. Identifying these novel therapeutic targets and combination therapies is an urgent need, as effective therapeutics for FLC are currently unavailable. Significance: Therapeutics informed by genomics have not yielded effective therapies for FLC. A functional screen identified TOPO1, HDAC inhibitors, and napabucasin as efficacious and synergistic with inhibition of Bcl-xL. Validation on cells dissociated directly from patient tumors demonstrates the ability for functional precision medicine in a solid tumor. This article is highlighted in the In This Issue feature, p. 2355
Comparing the efficacy of adipose‐derived and bone marrow‐derived cells in a rat model of posterolateral lumbar fusion
Perdomo‐Pantoja, Alexander , Elder, Benjamin D. , Cottrill, Ethan , Locke, John , Perdomo-Pantoja, Alexander , Holmes, Christina , Ishida, Wataru , Witham, Timothy F.

Mayo Clinic

Journal of Orthopaedic Research | June 3, 2021 | Volume: 40 | Issue: 4 | Pages: 909-916

10.1002/jor.25111 | PMID 34081344 Get It

AbstractAlthough bone marrow‐derived mesenchymal stem cells (BMCs) have been widely used in spinal fusion procedures, adipose‐derived stem cells (ASCs) offer a number of advantages as an alternative clinical cell source. This study directly compares the efficacy of ASCs and BMCs from the same donor animals to achieve successful fusion when combined with a clinical‐grade bone graft substitute in a rat lumbar fusion model. ASCs and BMCs were isolated from the same Lewis donor rats and grown to passage 2 (P2). Single‐level bilateral posterolateral intertransverse process lumbar fusion surgery was performed on syngeneic rats divided into three experimental groups: clinical‐grade bone graft substitute alone (CBGS); CBGS+ rat ASCs (rASC); and, CBGS+ rat BMCs (rBMC). Eight weeks postoperatively, fusion was evaluated via micro‐CT, manual palpation and histology. In vitro analysis of the osteogenic capacity of rBMCs and rASCs was also performed. Results indicated that the average fusion volume in the rASC group was the largest and was significantly larger than the CBGS group. Although the rASC group displayed the highest fusion rates via micro‐CT and manual palpation, this difference was not statistically significant. Cell‐seeded grafts showed more histological bone formation than cell‐free grafts. P2 rASCs and rBMCs displayed similar in vitro osteogenic differentiation capacities. Overall, this study showed that, when combined with a clinical‐grade bone graft substitute in a rat model, rASCs cells yielded the largest fusion masses and comparable fusion results to rBMCs. These results add to growing evidence that ASCs provide an attractive alternative to BMCs for spinal fusion procedures.
Multifactorial Wrist Pain Treated with Tenotomy of Anomalous Flexor Carpi Radialis Brevis
Bernstein, Ethan , Leonardelli, Dominic , Pulos, Nicholas , Pulos, Nicholas

Mayo Clinic

JBJS Case Connector | May 18, 2021 | Volume: 11 | Issue: 2 | Pages: No page available

10.2106/jbjs.cc.20.00102 | PMID 34003813 Get It

Case: We present a case of a 33-year-old left hand–dominant/right hand–involved active duty Navy sailor woman with volar radial wrist pain. She underwent scaphoid cyst excision and bone grafting as well as tenotomy. Intraoperatively, she was noted to have a flexor carpi radialis brevis (FCRB) tendon that was transected. After surgery, her 1-year outcomes demonstrated range of motion improved equivalent with her contralateral side, her visual analogue scale (VAS) pain score had decreased to 1, and her QuickDASH and Patient-Rated Wrist Evaluation improved. Conclusions: Our case represents 1-year outcome after surgical release of a FCRB. Our patient's pain and functional scores exceeded the minimal clinically important difference.
Abstract P103: Association Of Lipid Variability With Incident Alzheimers Disease And Alzheimers Disease Related Dementias
Moser, Ethan D. , Manemann, Sheila M., Rocca, Walter A. , Roger, Véronique L. , Decker, Paul A. , Killian, Jill M. , Moser, Ethan D , Larson, Nicholas B. , Sauver, Jennifer L. St. , Takahashi, Paul Y. , Mielke, Michelle M. , Olson, Janet E. , Decker, Paul A. , Bielinski, Suzette J.

Mayo Clinic

Circulation | May 18, 2021 | Volume: 143 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.143.suppl_1.p103 Get It

Background: Prevention strategies for Alzheimer’s disease and Alzheimer’s disease related dementias (AD/ADRDs) are urgently needed for reducing incidence. Intra-patient variability in lipid levels is a potentially modifiable risk factor for incident AD/ADRD. Although regular lipid measurements are a part of common clinical practice and longitudinal data routinely available in electronic health records (EHR), research examining this association between AD/ADRD and lipid variability across multiple lipid types remains scarce. Methods: All residents living in Olmsted County, MN on 1/1/2006 age ≥60 years without an AD/ADRD diagnosis were identified using Centers for Medicare & Medicaid Services diagnostic codes. Persons with ≥3 lipid measurements (total cholesterol or triglycerides) in the 5 years prior to index date were retained. Lipid variability was quantified using variability independent of the mean (VIM). Models were adjusted for traditional risk factors. Associations between lipid variability quintiles and incident AD/ADRD were assessed using Cox proportional hazards regression. Multiple imputation was used for missing covariates. Participants were followed through 2018 for incident AD/ADRD. Results: The final analysis included data on 11,551 participants with total cholesterol and 11,502 participants with triglycerides. Participants had a mean age of 71 (range 60-99) years, and were primarily white (96%). Females (54%) were also slightly more frequent than males. Median follow up was 12.9 years (range: 0-13). Participants in the highest quintile of variability for total cholesterol and triglycerides had a 20% increased risk of incident AD/ADRD. Similar results were found in the subset with complete covariate data. Conclusion: In a large EHR derived cohort, persons in the highest quintile of lipid variation had an increased risk of incident AD/ADRD. Further studies to identify the mechanisms behind this risk factor and replication of these results across a more diverse population are needed.
Abstract P102: Variability In Lipid Levels And Risk For Cardiovascular Disease: An Electronic Health Record-based Population Cohort Study
Manemann, Sheila M., Moser, Ethan D. , Roger, Véronique L. , Decker, Paul A. , Killian, Jill M. , Moser, Ethan D , Bielinski, Suzette J. , Sauver, Jennifer L. St. , Takahashi, Paul Y. , Olson, Janet E. , Decker, Paul A. , Larson, Nicholas B.

Mayo Clinic

Circulation | May 18, 2021 | Volume: 143 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.143.suppl_1.p102 Get It

Background: Larger within-patient variability of lipid levels has been associated with an increased risk of cardiovascular disease (CVD). However, measures of lipid variability are not currently used clinically. We investigated the feasibility of calculating lipid variability within a large electronic health record (EHR)-based population cohort and assessed associations with incident CVD. Methods: We identified all individuals ≥40 years of age who resided in Olmsted County, MN on 1/1/2006 (index date) without prior CVD. CVD was defined as myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention or stroke. Patients with ≥3 measurements of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and/or triglycerides during the 5 years before the index date were retained in the analyses. Lipid variability was calculated using variability independent of the mean (VIM). Patients were followed through 9/30/2017 for incident CVD (including CVD death). Cox regression was used to investigate the association between quintiles of lipid VIMs and incident CVD. Results: We identified 18,642 individuals (mean age 60; 55% female) who were free of CVD at baseline and VIM calculated for at least one lipid measurement. After adjustment, those in the highest VIM quintiles of total cholesterol had a 25% increased risk of CVD (Q5 vs. Q1 HR: 1.25, 95% CI: 1.08-1.45; Table). We observed similar results for LDL-C (Q5 vs. Q1 HR: 1.20, 95% CI: 1.04-1.39) and HDL-C (Q5 vs. Q1 HR: 1.25, 95% CI: 1.09-1.43). There was no association between triglyceride variability quintiles and CVD risk. Conclusion: In a large EHR-based population cohort, high variability in total cholesterol, HDL-C and LDL-C was associated with an increased risk of CVD, independently of traditional risk factors, suggesting it may be a target for intervention. Lipid variability can be calculated in the EHR environment but more research is needed to determine its clinical utility.